Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY
ISRCTN91737921Phase 3Completed
- Sponsor
- Penta Foundation
- Start
- Jun 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Dolutegravir arm with Standard of care arm (2 arms). Primary endpoint: Clinical or virological failure at 96 weeks. Started Jun 2015; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN91737921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN91737921.